123 related articles for article (PubMed ID: 8679444)
1. p16 mutations/deletions are not frequent events in prostate cancer.
Tamimi Y; Bringuier PP; Smit F; van Bokhoven A; Debruyne FM; Schalken JA
Br J Cancer; 1996 Jul; 74(1):120-2. PubMed ID: 8679444
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the p15, p16,and p18 genes in osteosarcoma.
Miller CW; Aslo A; Campbell MJ; Kawamata N; Lampkin BC; Koeffler HP
Cancer Genet Cytogenet; 1996 Feb; 86(2):136-42. PubMed ID: 8603340
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
4. Absence of p16/MTS1 gene mutations in human prostate cancer.
Chen W; Weghorst CM; Sabourin CL; Wang Y; Wang D; Bostwick DG; Stoner GD
Carcinogenesis; 1996 Dec; 17(12):2603-7. PubMed ID: 9006095
[TBL] [Abstract][Full Text] [Related]
5. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
7. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
8. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
10. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma.
Chen TC; Hsieh LL; Kuo TT; Ng KF; Wu Chou YH; Jeng LB; Chen MF
Anticancer Res; 2000; 20(3A):1621-6. PubMed ID: 10928081
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
[TBL] [Abstract][Full Text] [Related]
12. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the p16 gene in human neuroblastomas.
Castresana JS; Gómez L; García-Miguel P; Queizán A; Pestaña A
Mol Carcinog; 1997 Mar; 18(3):129-33. PubMed ID: 9115582
[TBL] [Abstract][Full Text] [Related]
14. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
15. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Marchini S; Codegoni AM; Bonazzi C; Chiari S; Broggini M
Br J Cancer; 1997; 76(2):146-9. PubMed ID: 9231912
[TBL] [Abstract][Full Text] [Related]
16. p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Borgonovo Brandter L; Heyman M; Rasool O; Liu Y; Grandér D; Einhorn S
Eur J Haematol; 1996 May; 56(5):313-8. PubMed ID: 8641406
[TBL] [Abstract][Full Text] [Related]
17. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients.
Patiño-García A; Sierrasesúmaga L
Cancer Genet Cytogenet; 1997 Oct; 98(1):50-5. PubMed ID: 9309118
[TBL] [Abstract][Full Text] [Related]
19. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Tahara H; Smith AP; Gaz RD; Arnold A
J Clin Endocrinol Metab; 1996 Oct; 81(10):3663-7. PubMed ID: 8855819
[TBL] [Abstract][Full Text] [Related]
20. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
